Please assess the completion status of the following clinical trial:

Trial Title: S0414 Cetuximab, Combo Chemo, and RT in Locally Advanced Esophageal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed primary squamous cell carcinoma or adenocarcinoma of the thoracic esophagus (≥ 20 cm from the incisors\*) or the gastroesophageal junction (confined to ≤ 2 cm into the gastric cardia)~  * Disease confined to the esophagus or peri-esophageal soft tissue~ * T4, M0 disease~ * Surgically unresectable disease by esophageal endoscopic ultrasonography OR medically unresectable disease~NOTE: \*Patients with primary disease \< 26 cm from the incisors must undergo bronchoscopy AND have negative cytology within the past 4 weeks~* Measurable or non-measurable disease by x-ray, CT scan and/or MRI, or physical examination within the past 4 weeks (for measurable disease) or within the past 6 weeks (for non-measurable disease)~* Tumor specimens available~* No recurrent disease~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* Zubrod 0-2~Life expectancy~* Not specified~Hematopoietic~* Absolute neutrophil count (ANC) ≥ 1,500/mm\^3~* White Blood Cell (WBC) count ≥ 3,000/mm\^3~* Platelet count ≥ 100,000/mm\^3~* Hemoglobin ≥ 10.0 g/dL~Hepatic~* Albumin normal~* Bilirubin normal~* Alkaline phosphatase normal~* Serum glutamic oxaloacetic transaminase (SGOT) or Serum glutamic pyruvic transaminase (SGPT) ≤ 2.5 times upper limit of normal~Renal~* Creatinine clearance \> 50 mL/min~Other~* Not pregnant or nursing~* Fertile patients must use effective contraception~* No prior severe reaction to monoclonal antibodies~* No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* No prior chemotherapy for esophageal cancer~Endocrine therapy~* Not specified~Radiotherapy~* No prior radiotherapy for esophageal cancer~* No concurrent intensity modulated radiotherapy~* No concurrent cobalt-60~Surgery~* No prior surgical resection or attempted surgical resection of esophageal cancer

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): Cetuximab+Cisplatin+Irinotecan followed by radiation therapy (RT) in Cycle 3.

Based on this trial design, predict the completion outcome and termination type (if applicable).